-
1
-
-
24344446871
-
Clinical practice: Diagnosis and initial management of Parkinson's disease
-
Nutt JG, Wooten GF. Clinical practice: diagnosis and initial management of Parkinson's disease. N Engl J Med 2005;353:1021-1027.
-
(2005)
N Engl J Med
, vol.353
, pp. 1021-1027
-
-
Nutt, J.G.1
Wooten, G.F.2
-
2
-
-
34547828793
-
Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease
-
Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007;6:826-829.
-
(2007)
Lancet Neurol
, vol.6
, pp. 826-829
-
-
Antonini, A.1
Poewe, W.2
-
3
-
-
37149051357
-
Heart valve regurgitation, pergolide use, and Parkinson disease: An observational study and meta-analysis
-
Corvol JC, Anzouan-Kacou JB, Fauveau E, et al. Heart valve regurgitation, pergolide use, and Parkinson disease: an observational study and meta-analysis. Arch Neurol 2007;64:1721-1726.
-
(2007)
Arch Neurol
, vol.64
, pp. 1721-1726
-
-
Corvol, J.C.1
Anzouan-Kacou, J.B.2
Fauveau, E.3
-
4
-
-
36348942365
-
Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide
-
Růzicka E, Linková H, Penicka M, Ulmanová O, Nová-ková L, Roth J. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide. J Neurol 2007;254:1575-1578.
-
(2007)
J Neurol
, vol.254
, pp. 1575-1578
-
-
Růzicka, E.1
Linková, H.2
Penicka, M.3
Ulmanová, O.4
Nová-ková, L.5
Roth, J.6
-
5
-
-
33947196215
-
Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease
-
Dewey RB 2nd, Reimold SC, O'Suilleabhain PE. Cardiac valve regurgitation with pergolide compared with nonergot agonists in Parkinson disease. Arch Neurol 2007;64: 377-380.
-
(2007)
Arch Neurol
, vol.64
, pp. 377-380
-
-
Dewey 2nd, R.B.1
Reimold, S.C.2
O'Suilleabhain, P.E.3
-
6
-
-
33845986031
-
Dopamine agonists and the risk of cardiac-valve regurgitation
-
Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356:29-38.
-
(2007)
N Engl J Med
, vol.356
, pp. 29-38
-
-
Schade, R.1
Andersohn, F.2
Suissa, S.3
Haverkamp, W.4
Garbe, E.5
-
7
-
-
33845974147
-
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
-
Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007;356: 39-46.
-
(2007)
N Engl J Med
, vol.356
, pp. 39-46
-
-
Zanettini, R.1
Antonini, A.2
Gatto, G.3
Gentile, R.4
Tesei, S.5
Pezzoli, G.6
-
8
-
-
33847759919
-
Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: A reader-blinded monocenter echocar-diography study
-
Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocar-diography study. Mov Disord 2007;22:234-238.
-
(2007)
Mov Disord
, vol.22
, pp. 234-238
-
-
Junghanns, S.1
Fuhrmann, J.T.2
Simonis, G.3
-
9
-
-
33749865531
-
Dopamine agonists and cardiac valvulopathy in Parkinson disease: A case-control study
-
Yamamoto M, Uesugi T, Nakayama T. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study. Neurology 2006;67:1225-1229.
-
(2006)
Neurology
, vol.67
, pp. 1225-1229
-
-
Yamamoto, M.1
Uesugi, T.2
Nakayama, T.3
-
10
-
-
33748363728
-
Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
-
Kim JY, Chung EJ, Park SW, Lee WY. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists. Mov Disord 2006;21:1261-1264.
-
(2006)
Mov Disord
, vol.21
, pp. 1261-1264
-
-
Kim, J.Y.1
Chung, E.J.2
Park, S.W.3
Lee, W.Y.4
-
11
-
-
33748311590
-
Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study
-
Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord 2006;21:1109-1113.
-
(2006)
Mov Disord
, vol.21
, pp. 1109-1113
-
-
Peralta, C.1
Wolf, E.2
Alber, H.3
-
12
-
-
23244443740
-
Valvular heart disease in patients taking pergolide
-
Waller EA, Kaplan J, Heckman MG. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2005;80: 1016-1020.
-
(2005)
Mayo Clin Proc
, vol.80
, pp. 1016-1020
-
-
Waller, E.A.1
Kaplan, J.2
Heckman, M.G.3
-
13
-
-
3242763710
-
Pergolide use in Parkinson disease is associated with cardiac valve regurgitation
-
Baseman DG, O'Suilleabhain PE, Reimold SC, Laskar SR, Baseman JG, Dewey RB Jr. Pergolide use in Parkinson disease is associated with cardiac valve regurgitation. Neurology 2004;63:301-304.
-
(2004)
Neurology
, vol.63
, pp. 301-304
-
-
Baseman, D.G.1
O'Suilleabhain, P.E.2
Reimold, S.C.3
Laskar, S.R.4
Baseman, J.G.5
Dewey Jr., R.B.6
-
14
-
-
4444351812
-
Severe mul-tivalvular heart disease: A new complication of the ergot derivative dopamine agonists
-
Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe mul-tivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004;19:656-662.
-
(2004)
Mov Disord
, vol.19
, pp. 656-662
-
-
Horvath, J.1
Fross, R.D.2
Kleiner-Fisman, G.3
-
15
-
-
11144354035
-
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
-
Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179-1183.
-
(2004)
Lancet
, vol.363
, pp. 1179-1183
-
-
Van Camp, G.1
Flamez, A.2
Cosyns, B.3
-
16
-
-
0141653014
-
Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide
-
Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003;61:859-861.
-
(2003)
Neurology
, vol.61
, pp. 859-861
-
-
Van Camp, G.1
Flamez, A.2
Cosyns, B.3
Goldstein, J.4
Perdaens, C.5
Schoors, D.6
-
17
-
-
0036894736
-
Valvular heart disease in patients taking pergolide
-
Pritchett AM, Morrison JF, Edwards TO, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc 2002;77:1280-1286.
-
(2002)
Mayo Clin Proc
, vol.77
, pp. 1280-1286
-
-
Pritchett, A.M.1
Morrison, J.F.2
Edwards, T.O.3
Schaff, H.V.4
Connolly, H.M.5
Espinosa, R.E.6
-
18
-
-
0038581961
-
The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease
-
Flowers CM, Racoosin JA, Lu SL, Beitz JG. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin Proc 2003:78:730-731.
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 730-731
-
-
Flowers, C.M.1
Racoosin, J.A.2
Lu, S.L.3
Beitz, J.G.4
-
19
-
-
33744457002
-
Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine
-
Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart 2006; 92:843-849.
-
(2006)
Heart
, vol.92
, pp. 843-849
-
-
Weber, M.1
Hamm, C.2
-
20
-
-
33645071970
-
Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation
-
Detaint D, Messika-Zeitoun D, Chen HH, et al. Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. Am J Cardiol 2006;97:1029-1034.
-
(2006)
Am J Cardiol
, vol.97
, pp. 1029-1034
-
-
Detaint, D.1
Messika-Zeitoun, D.2
Chen, H.H.3
-
21
-
-
4444340383
-
Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function
-
Eimer MJ, Ekery DL, Rigolin VH, Bonow RO, Carne-thon MR, Cotts WG. Elevated B-type natriuretic peptide in asymptomatic men with chronic aortic regurgitation and preserved left ventricular systolic function. Am J Cardiol 2004;94:676-678.
-
(2004)
Am J Cardiol
, vol.94
, pp. 676-678
-
-
Eimer, M.J.1
Ekery, D.L.2
Rigolin, V.H.3
Bonow, R.O.4
Carne-thon, M.R.5
Cotts, W.G.6
-
22
-
-
67650454167
-
Relationship between non-motor function and quality of life in Parkinson's disease; longitudinal study
-
Abstract
-
Watanabe H, Atsuta N, Ito M, et al. Relationship between non-motor function and quality of life in Parkinson's disease; longitudinal study. Rinsho Shinkeigaku 2007:47: 1015. Abstract.
-
(2007)
Rinsho Shinkeigaku
, vol.47
, pp. 1015
-
-
Watanabe, H.1
Atsuta, N.2
Ito, M.3
-
23
-
-
0026695663
-
Criteria for diagnosing Parkinson's disease
-
Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127.
-
(1992)
Ann Neurol
, vol.32
-
-
Calne, D.B.1
Snow, B.J.2
Lee, C.3
-
24
-
-
5644220292
-
Switching and combining of dopamine agonists
-
VI/19-23
-
Junghanns S, Glöckler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol 2004;251 suppl 6:VI/19-23.
-
(2004)
J Neurol
, Issue.SUPPL. 6
, pp. 251
-
-
Junghanns, S.1
Glöckler, T.2
Reichmann, H.3
-
25
-
-
0036827811
-
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: I: a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes
-
Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor: I: a multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002:303:791-804.
-
(2002)
J Pharmacol Exp Ther
, vol.303
, pp. 791-804
-
-
Millan, M.J.1
Maiofiss, L.2
Cussac, D.3
-
26
-
-
18144416218
-
Agonism at 5-HT2b receptor is not a class effect of the ergolines
-
Jahnichen S, Horowski R, Pertz HH. Agonism at 5-HT2b receptor is not a class effect of the ergolines. Eur J Pharmacol 2005:513:225-229.
-
(2005)
Eur J Pharmacol
, vol.513
, pp. 225-229
-
-
Jahnichen, S.1
Horowski, R.2
Pertz, H.H.3
-
27
-
-
0142008980
-
Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocar-diography
-
Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocar-diography. J Am Soc Echocardiogr 2003:16:777-802.
-
(2003)
J Am Soc Echocardiogr
, vol.16
, pp. 777-802
-
-
Zoghbi, W.A.1
Enriquez-Sarano, M.2
Foster, E.3
-
28
-
-
0015237841
-
The natural history of congestive heart failure: The Framingham study
-
McKee PA, Castelli WP, McNamara PM, et al. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-1446.
-
(1971)
N Engl J Med
, vol.285
, pp. 1441-1446
-
-
McKee, P.A.1
Castelli, W.P.2
McNamara, P.M.3
-
29
-
-
0027210870
-
Survival after the onset of congestive heart failure in Framingham Heart Study subjects
-
Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993:88:107-115.
-
(1993)
Circulation
, vol.88
, pp. 107-115
-
-
Ho, K.K.1
Anderson, K.M.2
Kannel, W.B.3
-
30
-
-
34948817624
-
In vivo model of drug-induced valvular heart disease in rats: Pergolide-induced valvular heart disease demonstrated with echocar-diography and correlation with pathology
-
Droogmans S, Franken PR, Garbar C, et al. In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocar-diography and correlation with pathology. Eur Heart J 2007:28:2156-2162.
-
(2007)
Eur Heart J
, vol.28
, pp. 2156-2162
-
-
Droogmans, S.1
Franken, P.R.2
Garbar, C.3
-
31
-
-
0031734994
-
Plasma B-type natriuretic peptide measurement in a multiphasic health screening program
-
Niinuma H, Nakamura M, Hiramori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998:90:89-94.
-
(1998)
Cardiology
, vol.90
, pp. 89-94
-
-
Niinuma, H.1
Nakamura, M.2
Hiramori, K.3
-
32
-
-
0036153284
-
Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population
-
Nakamura M, Endo H, Nasu M, Arakawa N, Segawa T, Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart 2002:87:131-135.
-
(2002)
Heart
, vol.87
, pp. 131-135
-
-
Nakamura, M.1
Endo, H.2
Nasu, M.3
Arakawa, N.4
Segawa, T.5
Hiramori, K.6
-
33
-
-
0037019567
-
Plasma brain natriuretic peptide concentration: Impact of age and gender
-
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002:40:976-982.
-
(2002)
J Am Coll Cardiol
, vol.40
, pp. 976-982
-
-
Redfield, M.M.1
Rodeheffer, R.J.2
Jacobsen, S.J.3
Mahoney, D.W.4
Bailey, K.R.5
Burnett Jr., J.C.6
-
34
-
-
2342572869
-
Greater change of orthostatic blood pressure is related to silent cerebral in-farct and cardiac overload in hypertensive subjects
-
Eguchi K, Kario K, Hoshide S, et al. Greater change of orthostatic blood pressure is related to silent cerebral in-farct and cardiac overload in hypertensive subjects. Hyper-tens Res 2004:27:235-241.
-
(2004)
Hyper-tens Res
, vol.27
, pp. 235-241
-
-
Eguchi, K.1
Kario, K.2
Hoshide, S.3
-
35
-
-
0038779278
-
3,4- Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro
-
Setola V, Hufeisen SJ, Grande-Allen KJ, et al. 3,4- Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol Pharmacol 2003:63:1223-1229.
-
(2003)
Mol Pharmacol
, vol.63
, pp. 1223-1229
-
-
Setola, V.1
Hufeisen, S.J.2
Grande-Allen, K.J.3
-
36
-
-
0036828154
-
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes
-
Newman-Tancredi A, Cussac D, Quen-tric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002:303:815-822.
-
(2002)
J Pharmacol Exp Ther
, vol.303
, pp. 815-822
-
-
Newman-Tancredi, A.1
Cussac, D.2
Quen-tric, Y.3
-
37
-
-
33748286837
-
Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease
-
Reichmann H, Bilsing A, Ehret R, et al. Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease. J Neurol 2006:253 suppl 4:iv36-iv38.
-
(2006)
J Neurol
, vol.253
, Issue.SUPPL. 4
-
-
Reichmann, H.1
Bilsing, A.2
Ehret, R.3
-
38
-
-
34547609651
-
Serial biomarker measurements in ambulatory patients with chronic heart failure: The importance of change over time
-
Miller WL, Hartman KA, Burritt MF, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation 2007:116:249-257.
-
(2007)
Circulation
, vol.116
, pp. 249-257
-
-
Miller, W.L.1
Hartman, K.A.2
Burritt, M.F.3
-
39
-
-
18444414911
-
B-type natriuretic peptide in organic mitral regurgitation: Determinants and impact on outcome
-
Detaint D, Messika-Zeitoun D, Avierinos JF, et al. B-type natriuretic peptide in organic mitral regurgitation: determinants and impact on outcome. Circulation 2005:111: 2391-2397.
-
(2005)
Circulation
, vol.111
, pp. 2391-2397
-
-
Detaint, D.1
Messika-Zeitoun, D.2
Avierinos, J.F.3
|